Last updated: May 2, 2023
Sponsor: Saint Petersburg State University, Russia
Overall Status: Active - Recruiting
Phase
N/A
Condition
Impotence
Infertility
Erectile Dysfunction
Treatment
PDE5 inhibitor (tadalafil) and BTL-6000 fSWT
PDE5 inhibitor (tadalafil)
Clinical Study ID
NCT05823506
ESWT_tadalafil_in_ED
Ages 20-45 Male
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:• Age 20 to 45;
- Married or have had a permanent sex partner for at least 3 months;
- IIEF-5 questionnaire scores below 20
Exclusion
Exclusion Criteria:
- History of previous use of PDE-5 inhibitors or fSWT;
- Patients with diabetes mellitus;
- Patients after the radical prostatectomy or major pelvic surgery;
- Patients with a confirmed neurological disease that may have caused the ED (MultipleSclerosis, Parkinson's Disease, spinal cord injury);
- Patients with contraindications to the use of PDE-5 inhibitors and/or fSWT;
Study Design
Total Participants: 36
Treatment Group(s): 2
Primary Treatment: PDE5 inhibitor (tadalafil) and BTL-6000 fSWT
Phase:
Study Start date:
February 01, 2023
Estimated Completion Date:
February 01, 2024
Study Description
Connect with a study center
SBPSU
Saint Petersburg,
Russian FederationActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.